CN1927863A - Preparation method of thienotetrahydropyridinacetic acid and salt thereof - Google Patents
Preparation method of thienotetrahydropyridinacetic acid and salt thereof Download PDFInfo
- Publication number
- CN1927863A CN1927863A CN 200510060719 CN200510060719A CN1927863A CN 1927863 A CN1927863 A CN 1927863A CN 200510060719 CN200510060719 CN 200510060719 CN 200510060719 A CN200510060719 A CN 200510060719A CN 1927863 A CN1927863 A CN 1927863A
- Authority
- CN
- China
- Prior art keywords
- preparation
- formula
- compound
- vii
- phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
The present invention provides preparation process of thienotetrahydro pyridyl acetic acid and its salt as shown in the expression V. The preparation process of thienotetrahydro pyridyl acetate includes one step of alkaline hydrolyzing the compound shown in the expression VII in 20-50 wt% concentration alkali aqua in the presence of phase transfer catalyst and at the pressure of 1-11 atm and temperature of 80-200 deg.c to obtain the compound shown in the expression V. The preparation process is simple and high in efficiency, and the present invention provides an important intermediate for the preparation of clopidogrel and other methyl thienotetrahydro pyridyl acetate compounds.
Description
(1) technical field
The present invention relates to the preparation method of a kind of thienotetrahydropyriacidcetic acidcetic and salt thereof, belong to chemical pharmacy field.
(2) background technology
Thienotetrahydropyriacidcetic acidcetic salt as formula V is the important intermediate of preparation methyl thienotetrahydropyridinacetate such as clopidogrel.Chinese patent application CN1487943A adopts formula (IV) compound under acid catalyst (example hydrochloric acid) effect, and reaction obtains the acidifying form (VI) of formula V compound in suitable solvent, but this method yield lower (below 40%) has limited its industrial application.
(3) summary of the invention
The invention provides a kind of technology is simple, yield is high preparation method suc as formula the thienotetrahydropyriacidcetic acidcetic and the salt (V) thereof of (VI).
Described thienotetrahydropyriacidcetic acidcetic salt (V) preparation method comprise the steps: formula (VII) compound in the alkali aqueous solution of 20-50%, under the phase-transfer catalyst effect under the 1-11atm pressure condition, a 80-200 ℃ alkaline hydrolysis gets described product;
Wherein X represents hydrogen, fluorine, chlorine, bromine or iodine atom, is preferably 2-chlorine; M is an alkalimetal ion, is preferably sodium or potassium ion.
Described phase-transfer catalyst as: quaternary ammonium salt, season phosphonium salt, molecular weight be polyoxyethylene glycol, the crown ether of 200-3000, be preferably: triethyl benzyl ammonia chloride, PEG400, PEG600, PEG800, catalyst levels is generally the 0.1-10% of reaction raw materials formula (VII) compound quality, is preferably 0.5-5%.
Described alkaline hydrolysis reacts in the mixing solutions that is recommended in buck and organic solvent and carries out described organic solvent such as C
1-C
8Alcohol or their arbitrary combination, be preferably one of following or more than one arbitrary combination: methyl alcohol, ethanol, propyl carbinol are preferably propyl carbinol again.The consumption of organic solvent is calculated as 1～5ml by every 1g formula (IV) compound.
The concentration of described alkali aqueous solution is considerable, and alkali aqueous solution is preferably the sodium hydroxide of 35-50% or the mixed solution of potassium hydroxide aqueous solution or their arbitrary proportions, and the equivalence ratio of alkali and formula (VII) compound is 1-20: 1, be preferably 15-20: 1.
The pressure of described alkaline hydrolysis reaction all refers to absolute pressure, is preferably 1-3atm, and temperature of reaction is preferably 90-120 ℃.
Described formula (VII) compound is optical isomer R or S, compound in the alkali aqueous solution of 30-50%, under the phase-transfer catalyst effect under the 1-3atm pressure condition, in 90-200 ℃ of alkaline hydrolysis 2-72 hour, described formula V racemoid.Any (chirality) optical isomer R or S thoroughly racemization simultaneously in the alkaline hydrolysis process for thoroughly making formula (VII) compound should improve temperature of reaction and pressure and prolong (racemization) reaction times.
The formula V compound promptly obtains compound (VI) through simple acidification.
The present invention also provides a kind of preparation method of the thienotetrahydropyriacidcetic acidcetic suc as formula (VI), comprises the steps:
(1) formula (IV) compound in the alkali aqueous solution of 20-50%, under the phase-transfer catalyst effect under the 1-11atm pressure condition, get thienotetrahydropyriacidcetic acidcetic salt in 80-200 ℃ of alkaline hydrolysis;
(2) thienotetrahydropyriacidcetic acidcetic salt promptly gets thienotetrahydropyriacidcetic acidcetic through acidifying;
Wherein X represents hydrogen, fluorine, chlorine, bromine or iodine atom, and M is an alkalimetal ion.
Described formula (VII) compound can be made in 60-130 ℃ of alkaline hydrolysis in the alkali aqueous solution of 5-20%, under the phase-transfer catalyst effect by formula (IV) compound; Here used phase-transfer catalyst is one of following: quaternary ammonium salt, season phosphonium salt, molecular weight be polyoxyethylene glycol, the crown ether of 200-3000.
Wherein X represents hydrogen, fluorine, chlorine, bromine or iodine atom.
Adopt preparation method of the present invention can obtain thienotetrahydropyriacidcetic acidcetic (VI) and salt (V) thereof simply, efficiently, for the preparation of methyl thienotetrahydropyridinacetates such as clopidogrel provides important intermediate.
(4) embodiment
The invention will be further described below in conjunction with embodiment, but protection scope of the present invention is not limited to this.
Synthesizing of embodiment 1 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) acetic acid sodium salt
Sodium hydroxide solution 320g with 50% and the methyl alcohol of 100ml, (±) of 61g-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide, phase-transfer catalyst TEBA, 1.0g place suitable reaction flask, the system back flow reaction is 18 hours then, stopped reaction.Cold filtration obtains target product 61g, yield 93%.
The raceme of target product is adjusted to pH=4～5 with acetic acid with system.Fully stir cooling, filter, drying gets the white solid powder compounds and is (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) acetate.
Synthesizing of embodiment 2 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) acetic acid sodium salt
With the propyl carbinol is solvent, and other obtains target product 63g with embodiment 1 step, yield 96%.
The raceme of product is adjusted to pH=4～5 with acetic acid with system.Fully stir cooling, filter, drying gets the white solid powder compounds and is (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) acetate.
Synthesizing of embodiment 3 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) acetic acid sodium salt
Sodium hydroxide solution 320g with 50% and the methyl alcohol of 100ml, (±) of 61g-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide, phase-transfer catalyst 18 hats 6,0.20g place suitable reaction flask, the system back flow reaction is 18 hours then, stopped reaction.Cold filtration obtains target product 63g, yield 96%.
Synthesizing of embodiment 4 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) acetic acid sodium salt
Sodium hydroxide solution 360g with 35% and the propyl carbinol of 100ml, (±) of 61g-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide, phase-transfer catalyst PEG4001.5g places suitable reaction flask, system pressure 4atm.The system back flow reaction is 18 hours then, stopped reaction.Cold filtration obtains target product 61g, yield 93%.
Synthesizing of embodiment 5 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) acetic acid sodium salt
Sodium hydroxide solution 450g with 35% and the propyl carbinol of 150ml, (±) of 61g-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide, phase-transfer catalyst 18 hats 6,0.20g places suitable reaction flask, system pressure 2atm.The system back flow reaction is 18 hours then, stopped reaction.Cold filtration obtains target product 63g, yield 96%.
Synthesizing of embodiment 6 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) acetic acid sodium salt
Sodium hydroxide solution 360g with 40% and the propyl carbinol of 100ml, (±) of 61g-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide, phase-transfer catalyst PEG6001.5g places suitable reaction flask, system pressure 2atm.The system back flow reaction is 18 hours then, stopped reaction.Cold filtration obtains target product 63g, yield 96%.
Synthesizing of embodiment 7 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) acetic acid sodium salt
Sodium hydroxide solution 360g with 40% and the methyl alcohol of 100ml, (±) of 61g-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide, phase-transfer catalyst PEG8001.5g places suitable reaction flask, system pressure 2atm.The system back flow reaction is 18 hours then, stopped reaction.Cold filtration obtains target product 62g, yield 94.5%.
Synthesizing of embodiment 8 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) potassium salt
Potassium hydroxide solution 360g with 50% and the methyl alcohol of 100ml, (±) of 61g-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide, phase-transfer catalyst TEBA, 1.0g place suitable reaction flask, the system back flow reaction is 18 hours then, stopped reaction.Cold filtration obtains target product 65g, yield 94.5%.
Synthesizing of embodiment 9 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) potassium salt
Potassium hydroxide solution 360g with 50% and the propyl carbinol of 100ml, (±) of 61g-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide, phase-transfer catalyst PEG400,1.5g place suitable reaction flask, the system back flow reaction is 18 hours then, stopped reaction.Cold filtration obtains target product 66g, yield 96%.
Synthesizing of embodiment 10 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) potassium salt
Potassium hydroxide solution 360g with 40% and the propyl carbinol of 100ml, (±) of 61g-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide, phase-transfer catalyst PEG800,1.5g place suitable reaction flask, the system back flow reaction is 18 hours then, stopped reaction.Cold filtration obtains target product 64g, yield 93%.
Synthesizing of embodiment 11 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) potassium salt
Potassium hydroxide solution 360g with 40% and the methyl alcohol of 100ml, (±) of 61g-(2-chloro-phenyl-)-(4,5,6,7-tetramethylene sulfide also [3,2-c] pyridine-5-yl) ethanamide, phase-transfer catalyst 18 hats 6,0.20g places suitable reaction flask, system pressure 2atm, the system back flow reaction is 18 hours then, stopped reaction.Cold filtration obtains target product 65g, yield 94.5%.Synthesizing of embodiment 12 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) potassium salt
Potassium hydroxide solution 450g with 35% and the propyl carbinol of 100ml, (±) of 61g-(2-chloro-phenyl-)-(4,5,6,7-tetramethylene sulfide also [3,2-c] pyridine-5-yl) ethanamide, phase-transfer catalyst PEG600,1.5g place suitable reaction flask, system pressure 4atm, the system back flow reaction is 18 hours then, stopped reaction.Cold filtration obtains target product 65g, yield 94.5%.
Synthesizing of embodiment 13 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide
Sodium hydroxide solution 450g with 5% and the methyl alcohol of 100ml, (±) of 60g-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) acetonitrile, phase-transfer catalyst TEBA, 1.0g place suitable reaction flask, the system back flow reaction is 20 hours then, stopped reaction.Cool to room temperature adds 600ml water, with n-butyl acetate extraction (150ml * 2), and washing, dry butylacetate phase, decompression is desolvated, and gets (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide 61g, yield 95.6%.
Products therefrom is differentiated as follows with IR spectrum, mass spectrum and 1H-NMR:
IR spectrum (cm-1): 1650 (s ,-C=O), 2333 (NH)
Mass spectrum (m/z): 307.2 (M+H)+
1H-NMR (CDC13): δ 7.4-7.5 (4H, m), 7.2 (1H, d), 7.0 (1H, s), 6.6 (1H, d), 6.0 (1H, s), 4.9 (1H, d), 3.6 (2H, q), 2.9 (4H, m) fusing points (Mp): 126-127.5 ℃.
Synthesizing of embodiment 14 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide
Sodium hydroxide solution 450g with 10% and the ethanol of 100ml, (±) of 60g-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) acetonitrile, phase-transfer catalysis PEG400,1.5g place suitable reaction flask, the system back flow reaction is 18 hours then, stopped reaction.Cool to room temperature adds 600ml water, with n-butyl acetate extraction (150ml * 2), and washing, dry butylacetate phase, decompression is desolvated, and gets (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide 60g, yield 94.2%.
Synthesizing of embodiment 15 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide
Sodium hydroxide solution 450g with 20% and the propyl carbinol of 100ml, (±) of 60g-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) acetonitrile, phase-transfer catalyst 18 hats 6,0.2g place suitable reaction flask, the system back flow reaction is 10 hours then, stopped reaction.Cool to room temperature,, add 600ml water, with n-butyl acetate extraction (150ml * 2), washing, dry butylacetate phase, decompression is desolvated, and gets (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide 62g, yield 97.2%.
Synthesizing of embodiment 16 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) acetic acid sodium salt
Sodium hydroxide solution 360g with 50% and the methyl alcohol of 100ml, (R) of 60g-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) ethanamide, phase-transfer catalyst TEBA, 1.0g place suitable reaction flask, the system back flow reaction is 15 hours then, stopped reaction.Cold filtration obtains target product 61g, yield 94.6%.
Synthesizing of embodiment 17 (±)-(2-chloro-phenyl-)-(4,5,6, the 7-tetramethylene sulfide is [3,2-c] pyridine-5-yl also) acetic acid sodium salt
With (S)-(2-chloro-phenyl-)-(4,5,6,7-tetramethylene sulfide also [3,2-c] pyridine-5-yl) ethanamide replace (R)-(2-chloro-phenyl-)-(4,5,6,7-tetramethylene sulfide also [3,2-c] pyridine-5-yl) ethanamide, other obtains target product 61g with embodiment 16, yield 94.6%.
Claims (13)
1, a kind of preparation method of the thienotetrahydropyriacidcetic acidcetic salt as formula V, comprise the steps: formula (VII) compound in the alkali aqueous solution of 20-50%, under the phase-transfer catalyst effect under the 1-11atm pressure condition, a 80-200 ℃ alkaline hydrolysis gets described product;
Wherein X represents hydrogen, fluorine, chlorine, bromine or iodine atom, and M is an alkalimetal ion.
2, preparation method as claimed in claim 1 is characterized in that described X is a 2-chlorine, and M is sodium or potassium ion.
3, preparation method as claimed in claim 1, it is characterized in that described phase-transfer catalyst is one of following: quaternary ammonium salt, season phosphonium salt, molecular weight be polyoxyethylene glycol, the crown ether of 200-3000, catalyst levels is the 0.1-10% of reaction raw materials formula (VII) compound quality.
4, preparation method as claimed in claim 3, it is characterized in that described phase-transfer catalyst is one of following: triethyl benzyl ammonia chloride, PEG400, PEG600, PEG800, catalyst levels are the 0.5-5% of reaction raw materials formula (VII) compound quality.
5, preparation method as claimed in claim 1 is characterized in that described alkaline hydrolysis carries out in the mixing solutions of water and organic solvent, described organic solvent is C
1-C
8Alcohol or their arbitrary combination, the consumption of organic solvent is calculated as 1～5ml by every 1g formula (VII) compound.
6, preparation method as claimed in claim 5 is characterized in that described organic solvent is one of following or more than one arbitrary combination: methyl alcohol, ethanol, propyl carbinol.
7, preparation method as claimed in claim 6 is characterized in that described organic solvent is a propyl carbinol.
8, as the described preparation method of one of claim 1-7, it is characterized in that described alkali aqueous solution is sodium hydroxide or potassium hydroxide aqueous solution or their mixed solution of 35-50%, the equivalence ratio of described alkali and formula (VII) compound is 1-20: 1.
9, preparation method as claimed in claim 8 is characterized in that the equivalence ratio of described alkali and formula (VII) compound is 15-20: 1.
10, preparation method as claimed in claim 1 is characterized in that the pressure of described alkaline hydrolysis reaction is 1-3atm, and temperature of reaction is 90-120 ℃.
11, preparation method as claimed in claim 8, it is characterized in that described formula (VII) compound is optical isomer R or S, compound in the alkali aqueous solution of 30-50%, under the phase-transfer catalyst effect under the 1-3atm pressure condition, 80-200 ℃ alkaline hydrolysis 2-72 hour, described formula V racemoid.
12, preparation method as claimed in claim 1 is characterized in that described formula (VII) compound is made in 60-130 ℃ of alkaline hydrolysis in the alkali aqueous solution of 5-20%, under the phase-transfer catalyst effect by formula (IV) compound;
Wherein X represents hydrogen, fluorine, chlorine, bromine or iodine atom.
13, a kind of preparation method of the thienotetrahydropyriacidcetic acidcetic suc as formula (VI) comprises the steps:
(1) formula (IV) compound in the alkali aqueous solution of 20-50%, under the phase-transfer catalyst effect under the 1-11atm pressure condition, a 80-200 ℃ alkaline hydrolysis gets thienotetrahydropyriacidcetic acidcetic salt;
(2) thienotetrahydropyriacidcetic acidcetic salt promptly gets thienotetrahydropyriacidcetic acidcetic through acidifying;
Wherein X represents hydrogen, fluorine, chlorine, bromine or iodine atom, and M is an alkalimetal ion.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510060719 CN100537576C (en) | 2005-09-08 | 2005-09-08 | Preparation method of thienotetrahydropyridinacetic acid and salt thereof |
| EP20060775625 EP1942110A4 (en) | 2005-09-08 | 2006-09-07 | Preparation of clopidogrel and its analogues methyl tetrahydrothienopyridine acetate compounds |
| US12/066,187 US7932391B2 (en) | 2005-09-08 | 2006-09-07 | Method for the preparation of clopidogrel and its analogues of methyl-tetrahydrothieno[3,2-C]pyridine acetate |
| PCT/CN2006/002316 WO2007028337A1 (en) | 2005-09-08 | 2006-09-07 | Preparation of clopidogrel and its analogues methyl tetrahydrothienopyridine acetate compounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510060719 CN100537576C (en) | 2005-09-08 | 2005-09-08 | Preparation method of thienotetrahydropyridinacetic acid and salt thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1927863A true CN1927863A (en) | 2007-03-14 |
| CN100537576C CN100537576C (en) | 2009-09-09 |
Family
ID=37858016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510060719 Active CN100537576C (en) | 2005-09-08 | 2005-09-08 | Preparation method of thienotetrahydropyridinacetic acid and salt thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100537576C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102120746A (en) * | 2011-01-31 | 2011-07-13 | 天津红日药业股份有限公司 | Clopidogrel hydrochloride crystal form II as well as preparation method and application thereof |
-
2005
- 2005-09-08 CN CN 200510060719 patent/CN100537576C/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102120746A (en) * | 2011-01-31 | 2011-07-13 | 天津红日药业股份有限公司 | Clopidogrel hydrochloride crystal form II as well as preparation method and application thereof |
| CN102120746B (en) * | 2011-01-31 | 2013-07-03 | 天津红日药业股份有限公司 | Clopidogrel hydrochloride crystal form II as well as preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100537576C (en) | 2009-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1884263A (en) | Pregabalin intermediate and process for preparing same | |
| US8871958B2 (en) | Method for preparing 5-chloromethyl-2-furfural using galactan derived from seaweed in two component phase | |
| CN1709871A (en) | S-(-)-indolyl-2-carboxylic acid synthesizing method | |
| CN1496986A (en) | Industrial synthetising strontium salt and method of its hydrate | |
| CN1789224A (en) | Preparation method of 2.3-difluoro-5-bromophenol | |
| CN1305843C (en) | Process for preparing 3-chloro-2-methyl thiobenzoxide | |
| CN109232178A (en) | Prepare the new method of high-purity hydroxytyrosol | |
| CN1680365A (en) | Novel synthesis and crystallization of piperazine ring-containing compounds | |
| CN1927863A (en) | Preparation method of thienotetrahydropyridinacetic acid and salt thereof | |
| CN1891807A (en) | Guerbet anion surfactant, and its preparing method and use | |
| CN1634933A (en) | Process for preparing ceftriaxone sodium | |
| CN101045702A (en) | Synthetic method of astaxanthin | |
| CN1942422A (en) | Method for producing hydrate of fluoroalkyl ketone | |
| JP4775936B2 (en) | Process for producing optically active mandelic acids | |
| CN102010327A (en) | Splitting method of (+/-)-2-(3-benzoyl)-phenylpropionic acid | |
| CN101048387A (en) | Process for the preparation of phenyl 2-pyrimidinyl ketones and their novel intermediates | |
| CN101065387A (en) | Composition containing phosphorylcholine and preparing method thereof | |
| CN106475136B (en) | A kind of azochlorosulfonate acid ion catalyst, preparation method and its application | |
| CN1927864A (en) | Preparation method of thienotetrahydropyridinacetic acid and salt thereof | |
| CN1955154A (en) | Preparation method of alkoxyl mandelic acid | |
| CN1671686A (en) | Process for producing n-monoalkyl-3-hydroxy-3-(2-thienyl)propanamine and intermediate | |
| CN101607914A (en) | Simple method for preparing to tert-butyl benzyl amine | |
| CN103664714B (en) | 2-substituting group-4-methylsulfonyl-phenyl-chloroform and preparation method thereof and application | |
| CN109134312B (en) | Preparation method of 2-phenyl acrylonitrile | |
| CN1566084A (en) | Novel optical pure water soluble diamine and derivative, preparation method and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |